FEED the BULL

Welcome to Feed the Bull - A home for investment information and interaction.

Tag: Arena Pharmaceuticals

Sort
E.g., 2013-05-21
E.g., 2013-05-21
Enter a comma separated list of user names.

The Food and Drug Administration has approved Arena Pharmaceutical's anti-obesity pill Belviq, the first new prescription drug for long-term weight loss to enter the U.S. market in over a decade.

Despite only achieving modest weight loss in clinical studies, the drug appeared safe enough to win the FDA's endorsement, amid calls from doctors for new weight-loss treatments.

The agency cleared the pill Wednesday for adults who are obese or are overweight with at least one medical complication, such as diabetes or high cholesterol.

ARNA, Arena Pharmaceuticals, Inc.

** ARNA and Eisai Inc. reported that the FDA has accepted for filing and review ARNA's resubmission of the New Drug Application for lorcaserin.

According to the company, the FDA considers the resubmission a complete, class 2 response, and assigned a new Prescription Drug User Fee Act (PDUFA) target date of June 27, 2012.

Crown Equity Holdings Inc. (OTCBB:CRWE) is pleased to announce its joint venture with Communication Expert Corporation.

The cornerstone of Crown Tele Services Inc. strategy is to meet the highest standards when it comes to delivering VoIP (Voice over Internet Protocol) communications solutions specifically designed to meet the business and residential market needs.

Proteonomix, Inc. (PROT.OB) is a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives.

PROT recently reported further developments with its Joint Venture Company, XGEN Medical LLC (”XGen”) towards implementing operations in the United Arab Emirates.

ADVERTISE WITH US